According to the Zhitong Finance App, Haixi New Pharmaceutical (02637) announced its 2026 interim results, with total operating revenue of 312 million yuan, up 3.8% year on year; net profit attributable to owners of the parent company was 81.0487 million yuan, down 24.8% year on year; basic earnings per share were 1.03 yuan.

As of the date of this announcement, the company's self-developed core innovative drug project HXP056, the candidate drug molecule HXP9428, is progressing simultaneously. China has completed phase I clinical trials. At this stage, phase II dose expansion studies and a second phase II clinical study using positive controls are being carried out. The US FDA phase II clinical application has been approved and has been granted fast track qualification by the US FDA; the C019199 osteosarcoma indications phase III clinical study was approved by the CDE and the first case was enrolled; the HXP089 project was used to treat glioblastoma ( Glioblastoma, GBM)'s new drug clinical trial application (IND) has been approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) to carry out relevant clinical research; the innovative drug pipeline has entered an intensive harvest period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.